Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s ...

Cardiovascular diseases remain the main cause of death globally, with rising cases among younger populations. The increasing ...

Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, ...

Dr Kshetrimayum Kala Singh“Cardiovascular disease is public health enemy number one”“Each year 18.6 million people die of cardiovascular disease in the developing world”This year also World Heart Day ...

Learn about heart failure causes, risk factors, prevention, and management in a webinar by The Hindu Wellness Series.

NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Omeicos Therapeutics completes enrollment in phase 2a PMD-OPTION study of OMT-28 in primary mitochondrial disease: Berlin, Germany Saturday, September 28, 2024, 13:00 Hrs [IST] Om ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

Family history is a strong indicator of genetic susceptibility to heart disease. Individuals with a family history of ...

A calcium transient measurement system utilizing human induced pluripotent stem cell-derived cardiomyocytes reveals the detrimental impact of inflammatory cytokines on cardiomyocyte relaxation and ...

A new analysis from SEQUOIA-HCM showed that treatment with aficamten was associated with beneficial changes in five indices reflecting structural, electrophysiologic and biomarker changes in patients ...